|
Lipodystrophy
|
0.300 |
Biomarker
|
disease |
CTD_human |
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
|
21417348 |
2011 |
|
Cardiomegaly
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Alpha-lipoic acid attenuates cardiac hypertrophy via downregulation of PARP-2 and subsequent activation of SIRT-1.
|
25281201 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Among them, the most promising compound, 11, showed excellent selective PARP-1 inhibitory activity (IC<sub>50</sub> = 29.5 nM) over PARP-2 (IC<sub>50</sub> > 1000 nM) and potent anticancer activities toward the SK-OV-3, Bel-7402 and HepG2 cancer cell lines (IC<sub>50</sub> = 2.39, 5.45, and 4.60 μM), along with inhibition of tumor growth in an in vivo SK-OV-3 cell xenograft model.
|
30844273 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Among them, the most promising compound, 11, showed excellent selective PARP-1 inhibitory activity (IC<sub>50</sub> = 29.5 nM) over PARP-2 (IC<sub>50</sub> > 1000 nM) and potent anticancer activities toward the SK-OV-3, Bel-7402 and HepG2 cancer cell lines (IC<sub>50</sub> = 2.39, 5.45, and 4.60 μM), along with inhibition of tumor growth in an in vivo SK-OV-3 cell xenograft model.
|
30844273 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
PARP-1 and PARP-2 activity in cancer-induced cachexia: potential therapeutic implications.
|
29016348 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
PARP-1 and PARP-2 activity in cancer-induced cachexia: potential therapeutic implications.
|
29016348 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
PARP-1, PARP-2 and PARP-7 are related to metabolic diseases such as diabetes, alcoholic and non-alcoholic fatty liver disease (AFLD, NAFLD), or on a broader perspective to Warburg metabolism in cancer or the metabolic diseases accompanying aging.
|
28013023 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
PARP-1, PARP-2 and PARP-7 are related to metabolic diseases such as diabetes, alcoholic and non-alcoholic fatty liver disease (AFLD, NAFLD), or on a broader perspective to Warburg metabolism in cancer or the metabolic diseases accompanying aging.
|
28013023 |
2017 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Our data suggest for the first time that a SNP in PARP2, rs878156, may together with other genetic variants modulate cancer specific survival in breast cancer patients depending on chemotherapy.
|
26674097 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Our data suggest for the first time that a SNP in PARP2, rs878156, may together with other genetic variants modulate cancer specific survival in breast cancer patients depending on chemotherapy.
|
26674097 |
2015 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Our results show that LUDLU-1 lacks the mutational signature that has been previously associated with tobacco exposure in other lung cancer subtypes, and suggests that DNA-repair efficiency is adversely affected; LUDLU-1 contains somatic mutations in TP53 and BRCA2, allelic imbalance in the expression of two cancer-associated BRCA1 germline polymorphisms and reduced transcription of a potentially endogenous PARP2 inhibitor.
|
24244370 |
2013 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Our results show that LUDLU-1 lacks the mutational signature that has been previously associated with tobacco exposure in other lung cancer subtypes, and suggests that DNA-repair efficiency is adversely affected; LUDLU-1 contains somatic mutations in TP53 and BRCA2, allelic imbalance in the expression of two cancer-associated BRCA1 germline polymorphisms and reduced transcription of a potentially endogenous PARP2 inhibitor.
|
24244370 |
2013 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These results suggest the involvement of PARP-2 or other PARPs, in the repair of DNA damage provoked by methylating agents, highlighting the importance of targeting both PARP-1 and PARP-2 for cancer therapy.
|
20464779 |
2010 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
These results suggest the involvement of PARP-2 or other PARPs, in the repair of DNA damage provoked by methylating agents, highlighting the importance of targeting both PARP-1 and PARP-2 for cancer therapy.
|
20464779 |
2010 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Analyses of PARP-2 expression at both mRNA and protein levels show significantly higher expression of PARP-2 in primary PCa tumors than in benign prostate tissues, and even more so in castration-resistant prostate cancer (CRPC) tumors.
|
31266892 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Positive PARP-2 and low miR-149 expression correlated with larger tumor mass size (P < 0.001), capsular and vascular invasion (P < 0.001), lymph node metastasis (P = 0.02), high histological grade (P < 0.001), TNM (P < 0.001), and BCLC grade (P = 0.001).
|
27300349 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function.
|
23810788 |
2013 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These have classically been with DNA damaging chemotherapy but the recently developed small molecule inhibitors of DNA repair enzymes such as Poly-ADP polymerases PARP-1 and PARP-2 have been shown to target tumour deficiencies in DNA repair as well sensitizing to DNA damaging therapeutics such as radiation and chemotherapy.
|
22015278 |
2011 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
Selective targeting of PARP-2 by genetic or pharmacological means blocks interaction between PARP-2 and FOXA1, which in turn attenuates AR-mediated gene expression and inhibits AR-positive PCa growth.
|
31266892 |
2019 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Selective targeting of PARP-2 by genetic or pharmacological means blocks interaction between PARP-2 and FOXA1, which in turn attenuates AR-mediated gene expression and inhibits AR-positive PCa growth.
|
31266892 |
2019 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
|
27486019 |
2016 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In all, 3 missense variants, PCTP, MCRS1, and ATRIP, demonstrated complete segregation and 1 missense variant, PARP2, demonstrated partial segregation with PC.
|
26585945 |
2016 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In all, 3 missense variants, PCTP, MCRS1, and ATRIP, demonstrated complete segregation and 1 missense variant, PARP2, demonstrated partial segregation with PC.
|
26585945 |
2016 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
|
27486019 |
2016 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The data indicate a novel PTTG3P-miR-383-CCND1/PARP2 axis in HCC tumorigenesis, suggesting that PTTG3P may be used as a potential therapeutic target in HCC.
|
31340767 |
2019 |